文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

肾脏替代治疗策略对β-内酰胺类血浆浓度的影响:BETAKIKI研究——一项随机对照试验的辅助研究

Impact of renal replacement therapy strategy on beta-lactam plasma concentrations: the BETAKIKI study-an ancillary study of a randomized controlled trial.
PubMed 文献 · Ann Intensive Care · 2023-02-25
一句话结论在严重急性肾损伤(KDIGO 3级)的ICU患者中,早期与延迟启动肾脏替代治疗对β-内酰胺类 trough 血药浓度达标率无显著影响(79.2% vs 81.4%,p=0.78)。

BETAKIKI研究是AKIKI随机对照试验的二次分析,纳入112例严重急性肾损伤(KDIGO 3级)的ICU患者,比较早期与延迟启动肾脏替代治疗策略对β-内酰胺类 trough 血药浓度的影响。主要终点为 trough 血药浓度高于4倍最低抑菌浓度(MIC)的患者比例,早期组为79.2%,延迟组为81.4%,两组无显著差异(p=0.78)。多因素分析显示,合并脓毒性休克(OR 3.95,95%CI 1.14–13.64,p=0.029)和较高的平均动脉压(OR 1.05,95%CI 1.01–1.10,p=0.013)与 trough 浓度达标概率较高独立相关。降钙素原水平变化、无儿茶酚胺天数及死亡率在 trough 浓度是否高于4倍MIC的患者间均无差异。

要点

  • 在严重急性肾损伤(KDIGO 3级)的ICU患者中,早期与延迟启动肾脏替代治疗的两组β-内酰胺类 trough 血药浓度高于4倍MIC的比例分别为79.2%和81.4%,无显著差异(p=0.78)。
  • 全人群中有74%(83/112)的患者入组时合并脓毒性休克,多因素分析显示脓毒性休克与 trough 浓度达标概率较高独立相关(OR 3.95,95%CI 1.14–13.64,p=0.029)。
  • 较高的平均动脉压亦与 trough 浓度达标概率较高独立相关(OR 1.05,95%CI 1.01–1.10,p=0.013)。
  • 降钙素原水平变化、无儿茶酚胺天数及死亡率在 trough 浓度是否高于4倍MIC的患者间均无差异。

适用人群与场景

  • ICU中严重急性肾损伤(KDIGO 3级)的危重患者,来自AKIKI随机对照试验的二次分析。

诊断标准与关键阈值

  • 严重急性肾损伤定义为KDIGO 3级。
  • β-内酰胺类 trough 血药浓度达标定义为 trough 浓度高于4倍最低抑菌浓度(MIC)。

研究设计与关键结果

  • 研究类型:随机对照试验的二次分析(BETAKIKI研究),纳入112例患者,早期肾脏替代治疗组53例,延迟组59例;83例(74%)入组时合并脓毒性休克。
  • 主要终点:全人群 trough β-内酰胺类血药浓度高于4倍MIC的比例为80.4%(n=90),早期组与延迟组分别为79.2%和81.4%,无显著差异(p=0.78)。
  • 多因素分析:脓毒性休克与 trough 浓度达标概率较高独立相关(OR 3.95,95%CI 1.14–13.64,p=0.029);较高的平均动脉压亦与 trough 浓度达标概率较高独立相关(OR 1.05,95%CI 1.01–1.10,p=0.013)。
  • 降钙素原水平变化、无儿茶酚胺天数及死亡率在 trough 浓度是否高于4倍MIC的患者间均无差异。

证据类型、等级与局限

  • 证据类型:随机对照试验的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在严重急性肾损伤(KDIGO 3级)的ICU患者中,肾脏替代治疗启动策略(早期 vs 延迟)未显著影响β-内酰胺类 trough 血药浓度。
  • 入组时合并脓毒性休克是与β-内酰胺类 trough 浓度达标概率较高相关的主要变量。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Sepsis prognosis correlates with antibiotic adequacy at the early phase. This adequacy is dependent on antibacterial spectrum, bacterial resistance profile and antibiotic dosage. Optimal efficacy of beta-lactams mandates concentrations above the minimal inhibitory concentration (MIC) of the targeted bacteria for the longest time possible over the day. Septic acute kidney injury (AKI) is the most common AKI syndrome in ICU and often mandates renal replacement therapy (RRT) initiation. Both severe AKI and RRT may increase outside target antibiotic concentrations and ultimately alter patient's prognosis.

PATIENTS AND METHODS: This is a secondary analysis of a randomized controlled trial that compared an early RRT initiation strategy with a delayed one in 620 critically ill patients undergoing severe AKI (defined by KDIGO 3). We compared beta-lactam trough concentrations between the two RRT initiation strategies. The primary outcome was the proportion of patients with sufficient trough plasma concentration of beta-lactams defined by trough concentration above 4 times the MIC. We hypothesized that early initiation of RRT could be associated with an insufficient antibiotic plasma trough concentration compared to patients allocated to the delayed strategy.

RESULTS: One hundred and twelve patients were included: 53 in the early group and 59 in the delayed group. Eighty-three patients (74%) had septic shock on inclusion. Trough beta-lactam plasma concentration was above 4 times the MIC breakpoint in 80.4% (n = 90) of patients of the whole population, without differences between the early and the delayed groups (79.2% vs. 81.4%, respectively, p = 0.78). On multivariate analysis, the presence of septic shock and a higher mean arterial pressure were significantly associated with a greater probability of adequate antibiotic trough concentration [OR 3.95 (1.14;13.64), p = 0.029 and OR 1.05 (1.01;1.10), p = 0.013, respectively). Evolution of procalcitonin level and catecholamine-free days as well as mortality did not differ whether beta-lactam trough concentration was above 4 times the MIC or not.

CONCLUSIONS: In this secondary analysis of a randomized controlled trial, renal replacement therapy initiation strategy did not significantly influence plasma trough concentrations of beta-lactams in ICU patients with severe AKI. Presence of septic shock on inclusion was the main variable associated with a sufficient beta-lactam concentration.

TRIAL REGISTRATION: The AKIKI trial was registered on ClinicalTrials.gov (Identifier: NCT01932190) before the inclusion of the first patient.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Roux D, Benichou N, Hajage D, et al. Impact of renal replacement therapy strategy on beta-lactam plasma concentrations: the BETAKIKI study-an ancillary study of a randomized controlled trial. Ann Intensive Care. 2023. PMID: 36840825. doi:10.1186/s13613-023-01105-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。